[go: up one dir, main page]

WO2001000183A3 - COMBINAISON D'INHIBITEURS DE MTP (PROTEINE DE TRANSFERT MICROSOMALE) ET INHIBITEURS DE HMG-CoA-REDUCTASE ET LEUR UTILISATION DANS DES MEDICAMENTS - Google Patents

COMBINAISON D'INHIBITEURS DE MTP (PROTEINE DE TRANSFERT MICROSOMALE) ET INHIBITEURS DE HMG-CoA-REDUCTASE ET LEUR UTILISATION DANS DES MEDICAMENTS Download PDF

Info

Publication number
WO2001000183A3
WO2001000183A3 PCT/EP2000/005410 EP0005410W WO0100183A3 WO 2001000183 A3 WO2001000183 A3 WO 2001000183A3 EP 0005410 W EP0005410 W EP 0005410W WO 0100183 A3 WO0100183 A3 WO 0100183A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitors
combination
hmg
coa reductase
medicaments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2000/005410
Other languages
German (de)
English (en)
Other versions
WO2001000183A2 (fr
Inventor
Rudi Gruetzmann
Ulrich Mueller
Hilmar Bischoff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Priority to AU56809/00A priority Critical patent/AU5680900A/en
Priority to CA002376881A priority patent/CA2376881A1/fr
Priority to EP00942056A priority patent/EP1196194A2/fr
Priority to JP2001505893A priority patent/JP2003503342A/ja
Publication of WO2001000183A2 publication Critical patent/WO2001000183A2/fr
Publication of WO2001000183A3 publication Critical patent/WO2001000183A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne l'utilisation d'une combinaison d'au moins un inhibiteur de MTP (constituant A) sélectionné et d'un inhibiteur de HMG-CoA-réductase (constituant B) pour lutter contre des maladies cardio-vasculaires. L'invention concerne également des médicaments contenant ladite combinaison et leur préparation.
PCT/EP2000/005410 1999-06-25 2000-06-13 COMBINAISON D'INHIBITEURS DE MTP (PROTEINE DE TRANSFERT MICROSOMALE) ET INHIBITEURS DE HMG-CoA-REDUCTASE ET LEUR UTILISATION DANS DES MEDICAMENTS Ceased WO2001000183A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU56809/00A AU5680900A (en) 1999-06-25 2000-06-13 Combination of mtp inhibitors and hmg-coa reductase inhibitors and the use thereof in medicaments
CA002376881A CA2376881A1 (fr) 1999-06-25 2000-06-13 Combinaison d'inhibiteurs de mtp (proteine de transfert microsomale) et inhibiteurs de hmg-coa-reductase et leur utilisation dans des medicaments
EP00942056A EP1196194A2 (fr) 1999-06-25 2000-06-13 COMBINAISON D'INHIBITEURS DE MTP (PROTEINE DE TRANSFERT MICROSOMALE) ET INHIBITEURS DE HMG-CoA-REDUCTASE ET LEUR UTILISATION DANS DES MEDICAMENTS
JP2001505893A JP2003503342A (ja) 1999-06-25 2000-06-13 ＭＴＰ阻害剤とＨＭＧ−ＣｏＡ還元酵素阻害剤との組み合わせ並びに薬剤におけるその使用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19929065A DE19929065A1 (de) 1999-06-25 1999-06-25 Kombination von MTP-Inhibitoren und HMG-CoA-Reduktase-Inhibitoren und ihre Verwendung in Arzneimitteln
DE19929065.2 1999-06-25

Publications (2)

Publication Number Publication Date
WO2001000183A2 WO2001000183A2 (fr) 2001-01-04
WO2001000183A3 true WO2001000183A3 (fr) 2001-05-10

Family

ID=7912459

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/005410 Ceased WO2001000183A2 (fr) 1999-06-25 2000-06-13 COMBINAISON D'INHIBITEURS DE MTP (PROTEINE DE TRANSFERT MICROSOMALE) ET INHIBITEURS DE HMG-CoA-REDUCTASE ET LEUR UTILISATION DANS DES MEDICAMENTS

Country Status (12)

Country Link
EP (1) EP1196194A2 (fr)
JP (1) JP2003503342A (fr)
AR (1) AR028996A1 (fr)
AU (1) AU5680900A (fr)
CA (1) CA2376881A1 (fr)
DE (1) DE19929065A1 (fr)
DO (1) DOP2000000022A (fr)
GT (1) GT200000099A (fr)
PE (1) PE20010302A1 (fr)
SV (1) SV2004000109A (fr)
UY (1) UY26218A1 (fr)
WO (1) WO2001000183A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10030375A1 (de) * 2000-06-21 2002-01-03 Bayer Ag Verwendung von MTP-Inhibitoren zur Senkung von ppTRL
KR100717098B1 (ko) * 2002-02-28 2007-05-10 니뽄 다바코 산교 가부시키가이샤 에스테르 화합물 및 그 의약 용도
EP1669345A4 (fr) 2003-08-29 2008-02-20 Japan Tobacco Inc Derive d'ester et utilisation medicale de celui-ci
US8101774B2 (en) 2004-10-18 2012-01-24 Japan Tobacco Inc. Ester derivatives and medicinal use thereof
FR2884831B1 (fr) * 2005-04-22 2007-08-10 Merck Sante Soc Par Actions Si Methode de criblage de composes inhibiteurs de la mtp
DE102011007272A1 (de) 2011-04-13 2012-10-18 Bayer Pharma Aktiengesellschaft Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung
US10905667B2 (en) 2018-07-24 2021-02-02 Bayer Pharma Aktiengesellschaft Orally administrable modified-release pharmaceutical dosage form
CN109053927A (zh) * 2018-08-08 2018-12-21 中山大学 一种含维生素b12基团的两亲性海藻酸钠衍生物及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998023593A1 (fr) * 1996-11-27 1998-06-04 Pfizer Inc. AMIDES INHIBANT LA SECRETION D'Apo B ET/OU LA PROTEINE MTP
WO1998050028A1 (fr) * 1997-05-01 1998-11-12 Bristol-Myers Squibb Company Combinaisons therapeutiques d'inhibiteur de mtp et de vitamine liposoluble destinees a reduire les taux de lipides seriques

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4435477A1 (de) * 1994-10-04 1996-04-11 Bayer Ag Cycloalkano-indol- und -azaindol-derivate
DE19546919A1 (de) * 1995-12-15 1997-06-19 Bayer Ag N-Heterocyclisch substituierte Phenylessigsäure-Derivate
DE19546918A1 (de) * 1995-12-15 1997-06-19 Bayer Ag Bicyclische Heterocyclen
DE19615265A1 (de) * 1996-04-18 1997-12-04 Bayer Ag Neue Pyridazino-, Pyrimido-, Pyrazino- und Triazino-indole

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998023593A1 (fr) * 1996-11-27 1998-06-04 Pfizer Inc. AMIDES INHIBANT LA SECRETION D'Apo B ET/OU LA PROTEINE MTP
WO1998050028A1 (fr) * 1997-05-01 1998-11-12 Bristol-Myers Squibb Company Combinaisons therapeutiques d'inhibiteur de mtp et de vitamine liposoluble destinees a reduire les taux de lipides seriques

Also Published As

Publication number Publication date
AR028996A1 (es) 2003-06-04
JP2003503342A (ja) 2003-01-28
WO2001000183A2 (fr) 2001-01-04
GT200000099A (es) 2001-12-13
CA2376881A1 (fr) 2001-01-04
SV2004000109A (es) 2004-05-07
AU5680900A (en) 2001-01-31
EP1196194A2 (fr) 2002-04-17
UY26218A1 (es) 2001-01-31
PE20010302A1 (es) 2001-04-12
DE19929065A1 (de) 2000-12-28
DOP2000000022A (es) 2008-08-15

Similar Documents

Publication Publication Date Title
AU6580000A (en) Pharmaceutical compositions comprising a hmg reductase inhibitor
AU2002360732A1 (en) Change inhibitors of dipeptidyl peptidase iv
WO2000066104A3 (fr) Composes inhibant ace-2 et leurs procedes d'utilisation
AU2002338806A1 (en) Pharmaceutical combinations of pde-v inhibitors and other agents
AU2002328494A1 (en) Drugs containing chymase inhibitor and ACE inhibitor as the active ingredients
WO2004000290A8 (fr) Composition pharmaceutique
AU3368400A (en) Aerosol compositions of hmg-coa reductase inhibitors for inhibiting inflammationassociated with pulmonary disease
AU1530001A (en) Inhibitor compositions
IL162325A0 (en) Hiv integrase inhibitor compounds and pharmaceutical compositions containing the same
HUP9801409A2 (hu) APO B szekréció és/vagy MTP-gátló hatású tetrahidroizokinolinszármazék, eljárás előállítására és ezt a vegyületet tartalmazó gyógyszerkészítmény
AU2003201071A1 (en) Stable pharmaceutical compositions comprising ace inhibitor(s)
AU2003250172A1 (en) Compositions comprising hmg-coa reductase inhibitor
WO2001056555A3 (fr) Utilisation d'inhibiteurs de cox-2 dans le traitement de la constipation
WO2001000183A3 (fr) COMBINAISON D'INHIBITEURS DE MTP (PROTEINE DE TRANSFERT MICROSOMALE) ET INHIBITEURS DE HMG-CoA-REDUCTASE ET LEUR UTILISATION DANS DES MEDICAMENTS
AU4543699A (en) Multibinding inhibitors of hmg-coa reductase
AU2002225796A1 (en) Tablet form of gas generant
AU2000238612A1 (en) Point of sale display
AUPQ629000A0 (en) Inhibition of fungi
WO2001000184A3 (fr) Combinaison d'inhibiteurs de proteine de transfert microsomale (mtp) et d'agents hypolipidemiants et leur utilisation dans des medicaments
EP1467978A4 (fr) Composes inhibiteurs de la lipase pancreatique, leur synthese et leur utilisation
WO2002096516A8 (fr) Compositions d'inhibiteurs selectifs de cyclooxygenase-2 et rayonnement pour l'inhibition ou la prevention de maladies cardiovasculaires
WO2001000189A3 (fr) Combinaison d'inhibiteurs de mtp et principes actifs agissant sur le metabolisme et leur utilisation dans les medicaments
AU2116201A (en) A therapeutic mixture of hmg-coa reductase inhibitors
AU7122400A (en) Inhibitor of vascular superoxide anion
AU2003252358A1 (en) MEDICINAL COMPOSITION CONTAINING HMG-CoA REDUCTASE INHIBITOR

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2000942056

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2376881

Country of ref document: CA

Ref country code: CA

Ref document number: 2376881

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 10019007

Country of ref document: US

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 505893

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 2000942056

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000942056

Country of ref document: EP